ImmunOs Therapeutics AG has developed a proprietary human leukocyte antigen (HLA)-based platform to generate a novel class of biologic therapeutics for the treatment of cancer and autoimmune disease.
The Company utilizes specific HLA molecules known to activate the immune system of patients with autoimmune disorders as the backbone of novel cancer immunotherapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs is also developing antibodies to block the activation of specific HLA molecules associated with autoimmune diseases.
ImmunOs is backed by an international consortium of top-tier investors, including Samsara Biocapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Mission BioCapital, and BioMed Partners.
The Company is a spin-off from the Universities of Zurich and Basel and based in Schlieren, Switzerland.